Royalty Pharma plc
Royalty Pharma plc (RPRX) Stock Overview
Explore Royalty Pharma plc’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
19.6B
P/E Ratio
25.67
EPS (TTM)
$1.78
ROE
0.12%
RPRX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Royalty Pharma plc (RPRX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 57.06, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $49.77.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 25.67 and a market capitalization of 19.6B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.